Targeting a protein to fight a common virus
Targeting Nuclear HSF1 as a Novel Anti-HCMV Strategy
This study is testing a new way to help people with weakened immune systems who are dealing with the human cytomegalovirus (HCMV) by using a special compound to block a protein that helps the virus grow, with the hope of creating better treatments that can both control the virus and get rid of infected cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Upstate Medical University NIH-funded |
| Lab location | 1 site (Syracuse, United States) |
| Project ID | NIH-11005730 on NIH RePORTER |
What this research studies
This research investigates a new approach to combat human cytomegalovirus (HCMV), which can cause severe illness in individuals with weakened immune systems. The study focuses on inhibiting a protein called heat shock factor 1 (HSF1) using a specific compound, DTHIB, which has shown promise in reducing the virus's ability to replicate and in killing infected cells. By targeting both the virus and the infected cells, this research aims to develop a more effective treatment strategy for HCMV. Patients may benefit from improved antiviral therapies that not only manage the virus but also eliminate the source of infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are immunocompromised individuals or neonates who are at high risk for severe HCMV infections.
Not a fit: Patients who are not infected with HCMV or those with fully functioning immune systems may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for HCMV, reducing the risk of severe disease in vulnerable populations.
How similar studies have performed: While this approach is innovative, similar strategies targeting viral replication and infected cells have shown promise in other contexts, suggesting potential for success.
Where this research is happening
Syracuse, United States
- Upstate Medical University — Syracuse, United States (Active)
Researchers
- Principal investigator: Chan, Gary Ching Tao — Upstate Medical University
- Study coordinator: Chan, Gary Ching Tao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.